Getting to HBV cure: The promising paths forward
Tóm tắt
Từ khóa
Tài liệu tham khảo
2020, Guidance for design and endpoints of clinical trials in chronic hepatitis B—report from the 2019 EASL‐AASLD HBV Treatment Endpoints Conference, J Hepatol, 72, 539, 10.1016/j.jhep.2019.11.003
2021, Association between seroclearance of hepatitis B surface antigen and long‐term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta‐analysis, Clin Gastroenterol Hepatol, 19, 463, 10.1016/j.cgh.2020.05.041
2017, Rnai‐based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis b virus DNA is a source of hbsag, Sci Transl Med, 9
2016, HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant, Gastroenterology, 151, 986, 10.1053/j.gastro.2016.07.012
2018, Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatology, 67, 1560, 10.1002/hep.29800
2010, Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers, Hepatology, 51, 1933, 10.1002/hep.23571
2010, Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)‐infection: a European perspective, J Hepatol, 52, 514, 10.1016/j.jhep.2010.01.014
2019, Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta‐analyses, Lancet Gastroenterol. Hepatol, 4, 227, 10.1016/S2468-1253(18)30308-X
2010, Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community‐based follow‐up study, Gastroenterology, 139, 474, 10.1053/j.gastro.2010.04.048
2015, Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection, Aliment Pharmacol Ther, 41, 949, 10.1111/apt.13170
2019, Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta‐analysis, Gastroenterology, 156, 635, 10.1053/j.gastro.2018.10.027
2021, The times they are a‐changing—a refined proposal for finite HBV nucleos(t)ide analogue therapy, J Hepatol, 75, 474, 10.1016/j.jhep.2021.04.040
2013, Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels, Hepatology, 58, 872, 10.1002/hep.26436
2019, Serum hepatitis B core‐related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients, J Hepatol, 70, 615, 10.1016/j.jhep.2018.11.030
2014, Linearized hepatitis B surface antigen and hepatitis B core‐related antigen in the natural history of chronic hepatitis B, Clin Microbiol Infect, 20, 1173, 10.1111/1469-0691.12739
2019, High level of hepatitis B core‐related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load, Gastroenterology, 157, 1518, 10.1053/j.gastro.2019.08.028
2021, Circulating pregenomic hepatitis B virus RNA is primarily full‐length in chronic hepatitis B patients undergoing nucleos(t)ide analogue therapy, Clin Infect Dis, 72, 2029, 10.1093/cid/ciaa1015
2018, Relationship between serum HBV‐RNA levels and intrahepatic viral as well as histologic activity markers in entecavir‐treated patients, J Hepatol, 68, 16, 10.1016/j.jhep.2017.08.021
2018, Natural history of serum HBV‐RNA in chronic HBV infection, J Viral Hepat, 25, 1038, 10.1111/jvh.12908
2020, Single hepatocytes show persistence and transcriptional inactivity of hepatitis B, JCI Insight, 5
2021, Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation, Gut, 70, 775, 10.1136/gutjnl-2020-321116
2021, Viral and immune factors associated with successful treatment withdrawal in HBeAg‐negative chronic hepatitis B patients, J Hepatol, 74, 1064, 10.1016/j.jhep.2020.11.043
2020, Pregenomic HBV RNA and hepatitis B core‐related antigen predict outcomes in hepatitis B e antigen‐negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy, Hepatology, 72, 42, 10.1002/hep.31026
2021, Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAg‐negative chronic hepatitis B, Clin Infect Dis, 72, 202, 10.1093/cid/ciaa013
2016, Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US—the ENUMERATE study, Aliment Pharmacol Ther, 43, 134, 10.1111/apt.13440
2010, Entecavir treatment for up to 5 years in patients with hepatitis B e antigen‐positive chronic hepatitis B, Hepatology, 51, 422, 10.1002/hep.23327
2019, Long‐term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5‐year results, Hepatol Int, 13, 260, 10.1007/s12072-019-09943-6
2006, A comparison of entecavir and lamivudine for HBeAg‐positive chronic hepatitis B, N Engl J Med, 354, 1001, 10.1056/NEJMoa051285
2008, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B, N Engl J Med, 359, 2442, 10.1056/NEJMoa0802878
2007, A one‐year trial of entecavir treatment in patients with HBeAg‐positive chronic hepatitis B, World J Gastroenterol, 13, 4264, 10.3748/wjg.v13.i31.4264
2007, Telbivudine versus lamivudine in patients with chronic hepatitis B, N Engl J Med, 357, 2576, 10.1056/NEJMoa066422
2003, Adefovir dipivoxil for the treatment of hepatitis B e antigen‐positive chronic hepatitis B, N Engl J Med, 348, 808, 10.1056/NEJMoa020681
2004, Four years of lamivudine treatment in Chinese patients with chronic hepatitis B, J Gastroenterol Hepatol, 19, 1276, 10.1111/j.1440-1746.2004.03428.x
2012, Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg‐positive chronic hepatitis B, Liver Int, 32, 137, 10.1111/j.1478-3231.2011.02641.x
2014, Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment, J Gastroenterol Hepatol, 29, 1028, 10.1111/jgh.12476
2011, Serum HBsAg decline during long‐term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss, J Infect Dis, 204, 415, 10.1093/infdis/jir282
2017, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 370, 10.1016/j.jhep.2017.03.021
2016, Asian‐Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update, Hepatol Int, 10, 1, 10.1007/s12072-015-9675-4
2018, Hepatitis B virus‐specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg‐negative chronic hepatitis B, J Hepatol, 69, 584, 10.1016/j.jhep.2018.05.004
2018, Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide‐analogue therapy discontinuation, J Clin Invest, 128, 668, 10.1172/JCI92812
2012, Sustained responses and loss of HBsAg in HBeAg‐negative patients with chronic hepatitis B who stop long‐term treatment with adefovir, Gastroenterology, 143, 629, 10.1053/j.gastro.2012.05.039
2017, Long‐term response after stopping tenofovir disoproxil fumarate in non‐cirrhotic HBeAg‐negative patients—FINITE study, J Hepatol, 67, 918, 10.1016/j.jhep.2017.07.012
2020, Response to discontinuation of long‐term nucleos(t)ide analogue treatment in HBeAg negative patients: results of the Stop‐NUC trial, J Hepatol, 73, S118, 10.1016/S0168-8278(20)30755-8
2019, Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study), Gut, 68, 2206, 10.1136/gutjnl-2019-318981
2018, Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen‐negative chronic hepatitis B, Hepatology, 68, 425, 10.1002/hep.29640
2020, HBsAg loss is higher among Caucasians compared to Asians after stopping nucleos(t)ide analogue therapy: results from a large, global, multi‐ethnic cohort of patients with chronic hepatitis B (RETRACT‐B STUDY), Hepatology, 72, 19A
2018, Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes, Aliment Pharmacol Ther, 47, 1170, 10.1111/apt.14560
2018, Long‐term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients, Clin Microbiol Infect, 24, 997, 10.1016/j.cmi.2017.12.013
2005, Peginterferon Alfa‐2a, lamivudine, and the combination for HBeAg‐positive chronic hepatitis B, N Engl J Med, 30, 2682
2005, Pegylated interferon alfa‐2b alone or in combination with lamivudine for HBeAg‐positive chronic hepatitis B: a randomised trial, Lancet, 365, 123, 10.1016/S0140-6736(05)17701-0
2004, Peginterferon Alfa‐2a alone, lamivudine alone, and the two in combination in patients with HBeAg‐negative chronic hepatitis B, N Engl J Med, 351, 1206, 10.1056/NEJMoa040431
2021, Ultra‐long‐term follow‐up of interferon alfa treatment for HBeAg‐positive chronic hepatitis B virus infection, Clin Gastroenterol Hepatol, 19, 1933, 10.1016/j.cgh.2020.09.004
2016, Combination of tenofovir disoproxil fumarate and peginterferon α‐2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B, Gastroenterology, 150, 134, 10.1053/j.gastro.2015.09.043
2017, Pegylated interferon Alfa‐2b add‐on treatment in hepatitis b virus envelope antigen‐positive chronic hepatitis B patients treated with nucleos(t)ide analogue: a randomized, controlled trial (PEGON), J Infect Dis, 215, 1085, 10.1093/infdis/jix024
2017, Effect on HBs antigen clearance of addition of pegylated interferon alfa‐2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen‐negative chronic hepatitis B and sustained undetectable plasma hepatitis, Lancet Gastroenterol Hepatol, 2, 177, 10.1016/S2468-1253(16)30189-3
2009, Factors that predict response of patients with hepatitis B e antigen‐positive chronic hepatitis B to peginterferon‐alfa, Gastroenterology, 137, 2002, 10.1053/j.gastro.2009.08.061
2014, Strategies to inhibit entry of HBV and HDV into hepatocytes, Gastroenterology, 147, 48, 10.1053/j.gastro.2014.04.030
2019, Excellent safety and effectiveness of high‐dose myrcludex‐B monotherapy administered for 48 weeks in HDV‐related compensated cirrhosis: a case report of 3 patients, J Hepatol, 71, 834, 10.1016/j.jhep.2019.07.003
2018, Novel potent capsid assembly modulators regulate multiple steps of the hepatitis B virus life cycle, Antimicrob Agents Chemother, 62, e00835
2011, The main Hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non‐nucleoside inhibitors of HBV replication, Antiviral Res, 92, 271, 10.1016/j.antiviral.2011.08.012
2017, Antiviral profiling of the capsid assembly modulator BAY41‐4109 on full‐length HBV genotype A‐H clinical isolates and core site‐directed mutants in vitro, Antiviral Res, 144, 205, 10.1016/j.antiviral.2017.06.016
2020, Antiviral activity and safety of the hepatitis B core inhibitor ABI‐ H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg‐negative chronic hepatitis B infection, J Hepatol, 73, S51, 10.1016/S0168-8278(20)30649-8
2020, Antiviral activity and safety of the hepatitis B core inhibitor ABI‐ H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg‐positive chronic hepatitis B infection in a long‐term extension study, J Hepatol, 73, S140, 10.1016/S0168-8278(20)30790-X
2021, Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection, J Hepatol, 75, S736
2015, The RNA sensor RIG‐I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus, Immunity, 42, 123, 10.1016/j.immuni.2014.12.016
2020, Liver toxicity in the Phase 2 Catalyst 206 trial of Inarigivir 400 mg daily added to a nucleoside in HBV EAg negative patients, J Hepatol, 73, S125, 10.1016/S0168-8278(20)30766-2
2017, Safety and efficacy of REP 2139 and pegylated interferon alfa‐2a for treatment‐naive patients with chronic hepatitis B virus and hepatitis D virus co‐infection (REP 301 and REP 301‐LTF): a non‐randomised, open‐label, phase 2 trial, Lancet Gastroenterol Hepatol, 2, 877, 10.1016/S2468-1253(17)30288-1
2020, Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa‐2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy, Gastroenterology, 158, 2180, 10.1053/j.gastro.2020.02.058
2021, Nucleic acid polymer therapy for hepatitis B virus: strong hepatitis B surface antigen decline but many unanswered questions, Gastroenterology, 160, 966, 10.1053/j.gastro.2020.06.097
2021, Safety, tolerability and pharmacokinetics (PK) of single and multiple doses of ALG‐010133, an S‐antigen transport inhibiting oligonucleotide polymer (STOPS) for the treatment of chronic hepatitis B [Abstract], J Hepatol, 75, S741
2004, Design and synthesis of novel N‐acetylgalactosamine‐terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor, J Med Chem, 47, 5798, 10.1021/jm049481d
2020, Preliminary safety and antiviral activity of VIR‐2218, an X‐targeting HBV RNAi therapeutic, in chronic hepatitis B patients, J Hepatol, 73, S50, 10.1016/S0168-8278(20)30647-4
2020, Short‐term treatment with RNA interference therapy, JNJ‐3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment, J Hepatol, 73, S20, 10.1016/S0168-8278(20)30597-3
2020, HBV RNAi inhibitor RG6346 in phase 1b–2a trial was safe, well‐tolerated, and resulted in substantial and durable reductions in serum HBsAg levels, Hepatology, 72, LO9
Efficacy and safety of the siRNA JNJ‐3989 and/or the capsid assembly modulator JNJ‐6379 for the treatment of chronic hepatitis B virus infection: results from the phase 2b REEF‐1 study, Hepatology
2021, Preliminary results from a phase 2 study evaluating VIR‐2218 alone and in combination with pegylated interferon alfa‐2a in participants with chronic hepatitis B infection, Hepatology, 74, 63A
2021, Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial, Nat Med, 27, 1725–, 10.1038/s41591-021-01513-4
2010, Zinc‐finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs, Mol Ther, 18, 947, 10.1038/mt.2010.20
2020, Permanent inactivation of HBV genomes by CRISPR/Cas9‐mediated non‐cleavage base editing, Mol Ther Nucleic Acids, 20, 480, 10.1016/j.omtn.2020.03.005
1983, Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers, J Clin Invest, 71, 1104, 10.1172/JCI110860
1985, Immunoregulation of the in vitro anti‐HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti‐hepatitis B vaccine recipients, Clin Exp Immunol, 60, 259
2018, Circulating and intrahepatic antiviral B cells are defective in hepatitis B, J Clin Invest, 128, 4588, 10.1172/JCI121960
2018, PD‐1 blockade partially recovers dysfunctional virus‐specific B cells in chronic hepatitis B infection, J Clin Invest, 128, 4573, 10.1172/JCI121957
1990, Cellular immune response to hepatitis B virus‐encoded antigens in acute and chronic hepatitis B virus infection, J Immunol, 145, 3442, 10.4049/jimmunol.145.10.3442
1999, Direct ex vivo analysis of hepatitis B virus‐specific CD8+ T cells associated with the control of infection, Gastroenterology, 117, 1386, 10.1016/S0016-5085(99)70289-1
2007, Characterization of hepatitis B virus (HBV)‐specific T‐cell dysfunction in chronic HBV infection, J Virol, 81, 4215, 10.1128/JVI.02844-06
2019, Phenotypic and functional differences of HBV core‐specific versus HBV polymerase‐specific CD8+ T cells in chronically HBV‐infected patients with low viral load, Gut, 68, 905, 10.1136/gutjnl-2018-316641
2018, Phenotype and function of HBV‐specific T cells is determined by the targeted epitope in addition to the stage of infection, Gut, 68, 893
2017, Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV‐specific CD8 T cells in chronic hepatitis B, Nat Med, 23, 327, 10.1038/nm.4275
2016, Distinct metabolic requirements of exhausted and functional virus‐specific CD8 T cells in the same host, Cell Rep, 16, 1243, 10.1016/j.celrep.2016.06.078
2009, The size of the viral inoculum contributes to the outcome of hepatitis B virus infection, J Virol, 83, 9652, 10.1128/JVI.00867-09
2003, CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection, J Virol, 77, 68, 10.1128/JVI.77.1.68-76.2003
1993, Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis, J Exp Med, 178, 1541, 10.1084/jem.178.5.1541
2002, Depletion of neutrophils blocks the recruitment of antigen‐nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus‐specific cytotoxic T lymphocytes, Proc Natl Acad Sci U S A, 99, 13717, 10.1073/pnas.172521999
2005, Platelets mediate cytotoxic T lymphocyte–induced liver damage, Nat Med, 11, 1167, 10.1038/nm1317
2001, Blocking chemokine responsive to gamma‐2/interferon (IFN)‐gamma inducible protein and monokine induced by IFN‐gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus‐specific cytotoxic T lymphocytes, J Exp Med, 194, 1755, 10.1084/jem.194.12.1755
2005, Toll‐like receptor signaling inhibits hepatitis B virus replication in vivo, J Virol, 79, 7269, 10.1128/JVI.79.11.7269-7272.2005
2013, GS‐9620, an oral agonist of Toll‐like receptor‐7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees, Gastroenterology, 144, 1508, 10.1053/j.gastro.2013.02.003
2021, Toll‐like receptor 8 agonist GS‐9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B, Hepatology, 73, 53, 10.1002/hep.31255
2017, Antiviral efficacy and host immune response induction during sequential treatment with SB 9200 followed by entecavir in woodchucks, PLoS One, 12
2015, AIC649 induces a bi‐phasic treatment response in the woodchuck model of chronic hepatitis B, PLoS One, 10
2002, Interferon‐regulated pathways that control hepatitis B virus replication in transgenic mice, J Virol, 76, 2617, 10.1128/JVI.76.6.2617-2621.2002
2000, Intrahepatic induction of alpha/beta interferon eliminates viral RNA‐containing capsids in hepatitis B virus transgenic mice, J Virol, 74, 4165, 10.1128/JVI.74.9.4165-4173.2000
2012, IFN‐α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome, J Clin Invest, 122, 529, 10.1172/JCI58847
2013, The third signal cytokine IL‐12 rescues the anti‐viral function of exhausted HBV‐specific CD8 T cells, PLoS Pathog, 9
2014, Toll‐like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver, PLoS Pathog, 10
1996, Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes, Immunity, 4, 25, 10.1016/S1074-7613(00)80295-2
2010, CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions, J Immunol, 184, 287, 10.4049/jimmunol.0902761
2016, Interferon‐γ and tumor necrosis factor‐α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis, Gastroenterology, 150, 194, 10.1053/j.gastro.2015.09.026
2018, Safety, efficacy and pharmacodynamics of vesatolimod (GS‐9620) in virally suppressed patients with chronic hepatitis B, J Hepatol, 68, 431, 10.1016/j.jhep.2017.10.027
2021, Therapeutic potential of TLR8 agonist GS‐9688 (selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators, Hepatology, 74, 55, 10.1002/hep.31695
2018, TLR7 agonist increases responses of hepatitis B virus‐specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues, Gastroenterology, 154, 1764, 10.1053/j.gastro.2018.01.030
2014, Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1, Immunity, 40, 961, 10.1016/j.immuni.2014.05.003
2007, The level of viral antigen presented by hepatocytes influences CD8 T‐cell function, J Virol, 81, 2940, 10.1128/JVI.02415-06
2021, Immunomodulation and RNA interference alter hepatitis B virus‐specific CD8 T cell recognition of infected HepG2‐NTCP, Hepatology
2013, Intrahepatic myeloid‐cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection, Nat Immunol, 14, 574, 10.1038/ni.2573
2018, Characterization of pattern recognition receptor expression and functionality in liver primary cells and derived cell lines, J Innate Immun, 10, 339, 10.1159/000489966
2015, Sustained efficacy and seroconversion with the Toll‐like receptor 7 agonist GS‐9620 in the Woodchuck model of chronic hepatitis B, J Hepatol, 62, 1237, 10.1016/j.jhep.2014.12.026
2017, New treatments to reach functional cure: rationale and challenges for emerging immune‐based therapies, Best Pract Res Clin Gastroenterol, 31, 337, 10.1016/j.bpg.2017.05.004
2012, Restored function of HBV‐specific T cells after long‐term effective therapy with nucleos(t)ide analogues, Gastroenterology, 143, 963, 10.1053/j.gastro.2012.07.014
2003, Transient restoration of anti‐viral T cell responses induced by lamivudine therapy in chronic hepatitis B, J Hepatol, 39, 595, 10.1016/S0168-8278(03)00292-7
2013, Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials, Expert Rev Vaccines, 12, 379, 10.1586/erv.13.15
2014, A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV‐specific T cell memory, Sci Transl Med, 6, 261ra153
2021, Randomized trial of a vaccine regimen to prevent chronic HCV infection, N Engl J Med, 384, 541, 10.1056/NEJMoa2023345
2019, Synergy of therapeutic heterologous prime‐boost hepatitis B vaccination with CpG‐application to improve immune control of persistent HBV infection, Sci Rep, 9, 10808, 10.1038/s41598-019-47149-w
2006, Correlation of antiviral T‐cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof‐of‐concept study, Gene Ther, 13, 1110, 10.1038/sj.gt.3302751
2019, Combined GS‐4774 and tenofovir therapy can improve HBV‐specific T‐cell responses in patients with chronic hepatitis, Gastroenterology, 157, 227, 10.1053/j.gastro.2019.03.044
2021, Therapeutic vaccine BRII‐179 restores HBV‐specific immune responses in patients with chronic HBV in a phase Ib/IIa study, JHEP Rep, 3, 100361, 10.1016/j.jhepr.2021.100361
2020, Effects of hepatitis B surface antigen on virus‐specific and global T cells in patients with chronic hepatitis B virus infection, Gastroenterology, 159, 652, 10.1053/j.gastro.2020.04.019
2010, Antiviral intrahepatic T‐cell responses can be restored by blocking programmed death‐1 pathway in chronic hepatitis B, Gastroenterology, 138, 682, 10.1053/j.gastro.2009.09.052
2014, Restoration of HBV‐specific CD8+ T cell function by PD‐1 blockade in inactive carrier patients is linked to T cell differentiation, J Hepatol, 61, 1212, 10.1016/j.jhep.2014.07.005
2019, Epigenetic signature of PD‐1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD‐1 blockade, Proc Natl Acad Sci U S A, 116, 14113, 10.1073/pnas.1903520116
2021, Memory‐like HCV‐specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection, Nat Immunol, 22, 229, 10.1038/s41590-020-00817-w
2013, T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion, Nat Immunol, 14, 603, 10.1038/ni.2606
2019, Anti‐PD‐1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study, J Hepatol, 71, 900, 10.1016/j.jhep.2019.06.028
2021, Checkpoint inhibition through small molecule‐induced internalization of programmed death‐ligand 1, Nat Commun, 12, 1222, 10.1038/s41467-021-21410-1
2014, Enhancing virus‐specific immunity in vivo by combining therapeutic vaccination and PD‐L1 blockade in chronic hepadnaviral infection, PLoS Pathog, 10
2021, Functional exhaustion of HBV‐specific CD8 T cells impedes PD‐L1 blockade efficacy in chronic HBV, Infection, 12, 648420
2020, Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection, J Exp Med, 217
2016, Clearing persistent extracellular antigen of hepatitis B virus: an immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination, J Immunol, 196, 3079, 10.4049/jimmunol.1502061
2020, Fc‐optimized antibodies elicit CD8 immunity to viral respiratory infection, Nature, 588, 485–, 10.1038/s41586-020-2838-z
2013, Results of a phase III clinical trial with an HBsAg‐HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings, J Hepatol, 59, 450, 10.1016/j.jhep.2013.05.003
2019, The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian patients with chronic hepatitis B: a systematic review, Hepatology, 70, 1045, 10.1002/hep.30474